Item 8.01 Other Events



On January 6, 2022, Hepion Pharmaceuticals, Inc. (the "Company") issued a press release announcing that the United States Adopted Names Council has adopted the nonproprietary name "rencofilstat" for the Company's lead drug candidate, CRV431. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.

Item 9.01 Financial Statements and Exhibits






(d) Exhibits



  99.1       Hepion Pharmaceuticals, Inc. Press Release dated January 6, 2022

104        Cover Page Interactive Data File. The cover page XBRL tags are embedded
           within the inline XBRL document.




                                      -2-

© Edgar Online, source Glimpses